Search clinical trials for: Eribulin mesilate

Total 1487 results

National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan

Active, not recruiting

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (LEADER)

Advanced Cancer | Leiomyosarcoma | Soft Tissue Sarcoma Adult | Liposarcoma

Taiwan
Eisai Korea Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Parkinson Disease

Korea, Republic of
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Active, not recruiting

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Sarcoma | Leiomyosarcoma | Liposarcoma | Undifferentiated Pleomorphic Sarcoma

United States
Centre Georges Francois Leclerc

Completed

Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin (EMEG-E-01)

Breast Cancer

France
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Nystagmus, Acquired | Nystagmus, Congenital Idiopathic

United Kingdom
Intensity Therapeutics, Inc.
Premier Research Group plc

Not yet recruiting

A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (INVINCIBLE-3)

Sarcoma,Soft Tissue
Laboratorios Sophia S.A de C.V.

Completed

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ (PRO-172)

Tolerability | Safety | Ocular Surface | Ocular Comfort

Mexico
Second Affiliated Hospital of Soochow University

Active, not recruiting

A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.

Salivation in Parkinson's Disease

China
Virginia G. Kaklamani
Eisai Inc.

Completed

Eribulin and Lenvatinib in Advanced Solid Tumors

Cancer | Solid Tumor

United States
Eisai Limited

Completed

Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors

Cancer

Netherlands
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
Bayer
Onyx Therapeutics, Inc.

Completed

Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

Neoplasms

Germany, France
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

Head and Neck Cancer

United States, Canada
Novartis

Completed

STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Sarcoma | Childhood Malignant Fibrous Histiocytoma of Bone

United States
European Organisation for Research and Treatment...

Completed

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Endometrial Cancer | Gastrointestinal Stromal Tumor

France, Denmark, Netherlands, Belgium, United Kingdom
Novartis Pharmaceuticals

Completed

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (Radix)

Progressive Gastrointestinal Stromal Tumor

Germany
Stanford University

Completed

Imatinib in Systemic Sclerosis

Scleroderma, Systemic

United States
Novartis Pharmaceuticals

Completed

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Life Threatening Diseases
UNICANCER

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Desmoid Tumor

France
University Hospital, Bordeaux
Novartis; Ministry of Health, France

Completed

Efficacy and Safety of Imatinib in Scleroderma (SCLEROGLIVEC)

Scleroderma, Systemic | Scleroderma, Localized

France
Maisonneuve-Rosemont Hospital
Hippocrate Research & Development

Unknown

Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors

Canada
SCRI Development Innovations, LLC
Novartis; Genentech, Inc.

Completed

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma
Wuhan Union Hospital, China
Yichang Humanwell Pharmaceutical Co., Ltd., China

Recruiting

PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function

Mechanically Ventilated Patients

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Breast Cancer

China
European Organisation for Research and Treatment...
UNICANCER; Grupo Espanol de Investigacion en Sarcomas; Italian Sarcoma Group

Completed

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

France, Australia, United Kingdom, Germany, Denmark, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Brain and Central Nervous System Tumors

United States
Novartis Pharmaceuticals

Completed

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) (CONVERT)

Gastrointestinal Stromal Tumors

Brazil
Novartis

Completed

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Leukemia

United States
Poitiers University Hospital
Novartis

Completed

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

Chronic Myeloid Leukemia

France
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor

Sarcoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU

Sedation in the ICU

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy

Sedation in the Upper Gastrointestinal Endoscopy

China
Asan Medical Center

Completed

Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation

Sarcoma | Gastrointestinal Stromal Tumors

Korea, Republic of
Southern California College of Optometry at Marshall...

Completed

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

Allergic Conjunctivitis

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

Sarcoma

United States
Novartis Pharmaceuticals

Completed

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor (GIST)

United States
Novartis Pharmaceuticals

Completed

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

Canada
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Novartis

Terminated

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Glioblastoma

Brazil
European Organisation for Research and Treatment...

Completed

Imatinib Mesylate in Treating Patients With Gliomas

Brain and Central Nervous System Tumors

France, Switzerland, Italy, Belgium, Austria, United Kingdom, Netherlands
Novartis Pharmaceuticals

Terminated

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Malignant Peripheral Nerve Sheath Tumors

Germany
Daniels, Craig E., M.D.
Novartis

Completed

Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung Disease
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Advanced Solid Tumors
University of Texas Southwestern Medical Center

Recruiting

Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

COVID-19 | SARS-CoV Infection

United States
Antipodean Pharmaceuticals, Inc.

Terminated

A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD) (MARVEL)

Non-alcoholic Fatty Liver Disease

United Kingdom
Antipodean Pharmaceuticals, Inc.

Completed

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

Chronic Hepatitis C

New Zealand
Peking University Cancer Hospital & Institute

Recruiting

Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut

Advanced Melanoma

China

Search clinical trials for: Eribulin mesilate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations